{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:12:52Z","timestamp":1786975972721,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd004161","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000}}],"reference-count":133,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004161.pub2","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T19:37:49Z","timestamp":1460662669000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Risperidone (depot) for schizophrenia"],"prefix":"10.1002","volume":"2016","author":[{"given":"Stephanie","family":"Sampson","sequence":"first","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Hosalli","sequence":"additional","affiliation":[{"name":"Seacroft Hospital; The Newsam Centre; York Road Leeds West Yorkshire UK LS14 6WB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek A","family":"Furtado","sequence":"additional","affiliation":[{"name":"University of Warwick; Division of Mental Health and Wellbeing, Warwick Medical School; Gibbet Hill Road Coventry West Midlands UK CV4 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Davis","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago; 1601 West Taylor St Chicago USA IL 60612"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-2006-946703","article-title":"A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study","volume":"39","author":"Bai","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004161.pub2-BIB0002|cit2","first-page":"174","article-title":"Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets","volume":"3","author":"Chue","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0003|cit3","unstructured":"Chue P Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS-INT-61 Promotional slides on file from Janssen-Cliag UK Ltd 2002"},{"issue":"5","key":"10.1002\/14651858.CD004161.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized control trial","volume":"73","author":"Covell","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long acting injectable in schizophrenia","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0006|cit6","first-page":"S1020","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine:Randomized, long-term, open-label, clinical trial results (constatre)","volume":"24","author":"Gaebel","year":"2009","journal-title":"Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal"},{"issue":"12","key":"10.1002\/14651858.CD004161.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial","volume":"35","author":"Gaebel","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0008|cit8","unstructured":"Medori R Wapenaar R de Arce R Rouillon F Gaebel W Cordes J Relapse prevention and effectiveness in schizophrenia of risperidone long-acting injectable (rlai) versus quetiapine or aripiprazole Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0009|cit9","first-page":"S1023","article-title":"Functional recovery in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (constatre)","volume":"24","author":"Rouillon","year":"2009","journal-title":"Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Schreiner A Rouillon F Eriksson L Burba B Raboch J Kaprinis G Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE) Biological Psychiatry 2009 382","DOI":"10.1016\/S0924-9338(09)71256-8"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Schreiner A de Arce R Eding E Marques-Teixeira J Milanova V Rancans E Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE) Biological Psychiatry 2009 381","DOI":"10.1055\/s-0029-1240096"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0012|cit12","first-page":"S1021","article-title":"Long-term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (constatre)","volume":"24","author":"Smeraldi","year":"2009","journal-title":"Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24-28; Lisbon Portugal"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Smeraldi E Cavallaro R Smalc VF Bidzan L Ceylan ME Schreiner A Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE) Biological Psychiatry 2009 389","DOI":"10.1016\/S0924-9338(09)71254-4"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00406-011-0220-8","article-title":"Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)","volume":"262","author":"Arce Cord\u00f3n","year":"March 2010","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0015|cit15","first-page":"157","article-title":"Injectible, long-acting risperidone effective","volume":"4","author":"Anonymous","year":"2001","journal-title":"Journal of Pharmacy Technology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004161.pub2-BIB0016|cit16","first-page":"S193","article-title":"Efficacy and safety of a novel long-acting risperidone formulation","volume":"17","author":"Kane","year":"2002","journal-title":"European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden)"},{"issue":"3","key":"10.1002\/14651858.CD004161.pub2-BIB0017|cit17","first-page":"291","article-title":"Long-acting risperidone microspheres for treatment of patients with schizophrenia","volume":"11","author":"Kane","year":"2001","journal-title":"European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004161.pub2-BIB0018|cit18","first-page":"S188","article-title":"Efficacy and safety of risperdal consta, the long-acting injection risperidone formulation","volume":"5","author":"Kane","year":"2002","journal-title":"International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada)"},{"issue":"3 Suppl.1","key":"10.1002\/14651858.CD004161.pub2-BIB0019|cit19","first-page":"174","article-title":"Efficacy and safety of a novel long-acting risperidone microspheres formulation","volume":"53","author":"Kane","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0020|cit20","unstructured":"Kane JM Eerdekens M Keith SJ Lesem M Karcher K Lindenmayer JP Efficacy and safety of risperdal consta (TM), a long-acting injection risperidone formulation RIS-USA-121 Promotional slides on file from Janssen-Cliag UK Ltd 2002"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD004161.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1016\/S0924-977X(02)80495-3","article-title":"Long-acting injectable risperidone: Efficacy and safety","volume":"12","author":"Kane","year":"2002","journal-title":"European Neuropsychopharmacology: Journal of the European College of Neuropsychopharmacology (15th ECNP Congress; October 5-9, 2002, Barcelona-Spain"},{"issue":"6","key":"10.1002\/14651858.CD004161.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.105.017020","article-title":"Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study","volume":"191","author":"Keks","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0024|cit24","unstructured":"Keks N Khan A Augustyns I Rabinowitz J Ingham M Non-inferiority efficacy trial of risperidone long-acting injection (RLAI) vs. olanzapine tablets (OLA) Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD004161.pub2-BIB0026|cit26","first-page":"23","article-title":"A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia","volume":"7","author":"MacFadden","year":"2010","journal-title":"Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0027|cit27","unstructured":"Pandina G Lane R Gassmann-Mayer C Hough D Remmerie B Simpson G A randomised double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia Proceedings of the 27th International College of Neuropsychopharmacology Congress; 2010 June 6-10; Hong Kong 2010"},{"issue":"9","key":"10.1002\/14651858.CD004161.pub2-BIB0028|cit28","first-page":"77","article-title":"A randomized double blind study of flexible doses of paliperidone palmitate and risperidone long acting therapy in patients with schizophrenia","volume":"67","author":"Pandina","year":"2010","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0030|cit30","unstructured":"Quinn A Camacho F Mitchell D Chue P Malla A Open-label randomized exploratory investigation of Risperdal* Consta* and oral antipsychotics treatment of early psychosis Autumn Conference of the International Society for CNS Clinical Trials and Methodology, October 1-3 Marina Del Rey, California 2012"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.11m07070","article-title":"Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia","volume":"73","author":"Barnett","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD004161.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","article-title":"Long- acting risperidone and oral antipsychotics in unstable schizophrenia","volume":"364","author":"Rosenheck","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004161.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1517\/14656566.2010.499125","article-title":"Long acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention","volume":"11","author":"Agid","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD004161.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00004714-200006000-00002","article-title":"Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia","volume":"20","author":"Bouchard","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD004161.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14740338.2010.506712","article-title":"Long acting atypical injectable antipsychotics in the treatment of schizophrenia: Saftey and tolerability review","volume":"9","author":"Canas","year":"2010","journal-title":"Expert Opinion on Drug Saftey"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0920-9964(12)70783-1","article-title":"Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia","volume":"136","author":"DeMartinis","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0037|cit37","unstructured":"Chue P Devos E Duchesne I Leal A Mehnert A Hospitalization rates in patients during long-term treatment with long-acting risperidone injection Poster presented at the XXIII CINP Congress, Montreal, Canada."},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004161.pub2-BIB0038|cit38","first-page":"174","article-title":"Long-term safety of long-acting risperidone microspheres","volume":"3","author":"Eerdekens","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0039|cit39","unstructured":"Fleischhacker WW Eerdekens M Xie Y Beauclair L Sauret H Chrzanowski W Long-term saftey and efficacy of risperdal consta(TM) a long-acting injection formulation of risperidone ACNP, Hawaii, USA, December 2001 (Promotional slides on file from Janssen-Cliag UK Ltd) 2002"},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0040|cit40","first-page":"1","article-title":"Treatment delivery: a hope for the future","volume":"56","author":"Eerdekens","year":"2002","journal-title":"Nordic Journal of Psychiatry (Abstracts of The Scandinavian College of Neuro-Psychopharmacology Annual Conference; 2002 10-13 Apr; Juan-Les-Pins, France)"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0041|cit41","unstructured":"Gallhofer B Cognitive dysfunction in schizophrenia: comparison of treatment with a novel atypical antipsychotic agent versus conventional neuroleptic drugs 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy 1995"},{"issue":"9","key":"10.1002\/14651858.CD004161.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"e1168","DOI":"10.4088\/JCP.12m07642","article-title":"Bl-1020, a new -aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study","volume":"73","author":"Geffen","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0043|cit43","unstructured":"Gefvert O Nyberg S Persson P Helklin L Bjorner A Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Kogeorgos J Kanellos P Michalakeas A Ioannidis J Sulpiride and risperidone vs. \"classical neuroleptics\" in schizophrenia: a follow-up study 8th Congress of the European College of Neuropsychopharmacology; 1995 Sep 30 - Oct 4; Venice, Italy 1995","DOI":"10.1016\/0924-977X(95)90548-R"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0045|cit45","unstructured":"Koola MM Bustillo J Lauriello J Insight and its to baseline characteristics of schizophrenia patients randomized to long acting injectable risperidone or oral atypical antipsychotics: results from the proactive study Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28- Apr 1; San Diego, CA Oxford Univ Press 2009"},{"issue":"3","key":"10.1002\/14651858.CD004161.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0920-9964(94)00041-6","article-title":"Five factor model of schizophrenia - replication across samples","volume":"14","author":"Lindenmayer","year":"1995","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S508","DOI":"10.1016\/S0924-977X(14)70813-2","article-title":"AZD8529, a positive allosteric modulator at the MGGLUR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study","volume":"24","author":"Litman","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/S0920-9964(14)70518-3","article-title":"AZD8529, a positive allosteric modulator at the mGLuR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study","volume":"153","author":"Litman","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0049|cit49","unstructured":"Littrell KH Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA 1999 95283955"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0050|cit50","unstructured":"\u5218\u82b3 \u5f20\u70b3\u594e \u8c22\u4e3d\u7434 \u90d1\u82f1\u541b \u6b27\u5efa\u519b \u5434\u4ec1\u5bb9 \u7c73\u8bfa\u73af\u7d20\u8f85\u52a9\u6cbb\u7597\u65e9\u671f\u7cbe\u795e\u5206\u88c2\u75c7\u9634\u6027\u75c7\u72b6\u7684\u53cc\u76f2\u3001\u968f\u673a\u3001\u5bf9\u7167\u7814\u7a76 \u957f\u6cbb\u533b\u5b66\u9662\u5b66\u62a5 2014 30 2"},{"issue":"3","key":"10.1002\/14651858.CD004161.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/hup.1108","article-title":"Switching stable patients with schizophrenia from depot and oral antipsychotics to long acting injectable risperidone: Efficacy, quality of life and functional outcome","volume":"25","author":"Lloyd","year":"2010","journal-title":"Human Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/YIC.0b013e3283347cbf","article-title":"Risperidone long acting therapy in stable patients with recently diagnosed schizophrenia","volume":"25","author":"MacFadden","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0053|cit53","unstructured":"Macfadden W Bossie C Turkoz I Diekamp B Ibach B Haskins JT Effect of long acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients Proceedings of the XXVI Collegium Internationale Neuro Psychopharmacologicum congress; 2008 Jul 13-17; Munich, Germany 2008"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0054|cit54","unstructured":"Macfadden W Bossie C Turkoz I Dorson P Haskins T Effect of long acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/JCP.0b013e3181accfd9","article-title":"The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder","volume":"29","author":"McClure","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/S0920-9964(12)70827-7","article-title":"Effect of lurasidone on weight and metabolic parameters: A comprehensive database analysis","volume":"136","author":"Pikalov","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD004161.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2010.07.016","article-title":"Long acting injectable risperidone in treatment refractory patients: A 14 week open label pilot study","volume":"123","author":"Procyshyn","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004161.pub2-BIB0058|cit58","first-page":"157","article-title":"Schizophrenia cohort study of olanzapine v risperidone in the elderly (score): analysis of conversion period","volume":"11","author":"Ritchie","year":"1999","journal-title":"International Psychogeriatrics (Abstracts of the 9th Congress of the International Psychogeriatric Association, \"Challenges for the New Millennium: Professional, Cultural and Regional Diversity\"; 1999 Aug 15-20; Vancouver, Canada)"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004161.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(00)80313-2","article-title":"Longer-term effects of switching from typical to atypical antipsychotics in patients with stable schizophrenia","volume":"10","author":"Robinson","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0060|cit60","first-page":"A99","article-title":"Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy","volume":"21","author":"Schmechtig","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0061|cit61","unstructured":"Schmechtig A Lees J Dawson G Dourish C Craig K Deakin B Effects of high schizotypy on control of eye movements: Modulation by antipsychotic drugs and nicotine Proceedings of the 49th Annual Meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4088\/JCP.v67n0804","article-title":"A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/j.1440-1614.2000.00813.x","article-title":"Community Treatment Orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission","volume":"5","author":"Vaughan","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004161.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hup.1104","article-title":"Saftey and efficacy of long acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6 month open label trial in Asian patients","volume":"25","author":"Verma","year":"2010","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0065|cit65","unstructured":"Weiden PJ Goldfinger SM Hindi A Sunakawa A Schooler NR Acceptance of a recommendation of a long acting antipsychotic route in first episode schizophrenia: initial findings of a prospective randomized study Proccedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"issue":"10","key":"10.1002\/14651858.CD004161.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.09m05284yel","article-title":"A randomized controlled trial of long acting injectable risperidone vs continuation on oral atypical antipsychotics for first episode schizophrenia patients: initial adherence outcome","volume":"70","author":"Weiden","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD004161.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.11m06905","article-title":"Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: A randomized effectiveness study","volume":"73","author":"Weiden","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD004161.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3371\/CSRP.4.3.3","article-title":"Insight : Demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder","volume":"4","author":"Wiffen","year":"2010","journal-title":"Clinical Schizophrenia and Related Psychoses"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Nasrallah H Duchesne I Mehnert A Janagap C Long-acting risperidone improves quality of life Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002","DOI":"10.1016\/S0924-977X(02)80391-1"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004161.pub2-BIB0070|cit70","first-page":"S189","article-title":"Long-acting risperidone injection improves quality of life","volume":"5","author":"Nasrallah","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004161.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/S0924-977X(02)80391-1","article-title":"Long-acting, injectable risperidone - the first long-acting, atypical antipsychotic - improves quality of life","volume":"12","author":"Nasrallah","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD004161.pub2-BIB0072|cit72","first-page":"1150","article-title":"Correction","volume":"65","author":"Nasrallah","year":"2004","journal-title":"Journal of Clinical Psychological Medicine [\u4e34\u5e8a\u7cbe\u795e\u533b\u5b66\u6742\u5fd7]"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4088\/JCP.v65n0412","article-title":"Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone","volume":"65","author":"Nasrallah","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Segarra R Ojeda N Garcia J Pena J Bravo E Eguiluz JI Risperidone injectable long acting treatment vs other oral antipsychotics in first episode psychosis: One year longitudinal study Schizophrenia Research 2010 495","DOI":"10.1016\/j.schres.2010.02.939"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0075|cit75","unstructured":"Turner T Risperidone depot v risperidone tablets: a non-inferiority efficacy trial in subjects with schizophrenia National Research Register (http:\/\/www.update-software.com\/National\/) 2000"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"British Journal of Psychiatry"},{"issue":"7066","key":"10.1002\/14651858.CD004161.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0078|cit78","volume-title":"Diagnostic and sStatistical Manual of Mental Disorders : DSM-IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"7108","key":"10.1002\/14651858.CD004161.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0081|cit81","unstructured":"BMJ Group and Pharmaceautical Press British National Formulary No. 63. Antipsychotic drugs BNF 2012"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0082|cit82","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0083|cit83","unstructured":"Cost-Effectiveness Analysis Registry (CEA) https:\/\/research.tufts-nemc.org\/cear4\/ accessed 11\/09\/13"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0084|cit84","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Science"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0085|cit85","unstructured":"Clarke M Oxman AD Cochrane Collaboration Handbook Cochrane Database of Systematic Reviews 2002"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2165\/00003495-197714040-00002","article-title":"Antipsychotic drugs: clinical pharmacology and therapeutic use","volume":"14","author":"Davis","year":"1977","journal-title":"Drugs"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD004161.pub2-BIB0089|cit89","first-page":"2S","article-title":"The natural course of schizophrenia and effective maintenance drug treatment","volume":"6","author":"Davis","year":"1986","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0090|cit90","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD004161.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD004161.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004161.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophrenia Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD004161.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7273","key":"10.1002\/14651858.CD004161.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD004161.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Guy W Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology ECDEU Assessment Manual for Psychopharmacology 1976 217 22","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0100|cit100","unstructured":"Health Economic Evaluation Database (HEED) Online ISBN: 9780470510933 10.1002\/9780470510933"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0102|cit102","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0105|cit105","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005237.pub2","article-title":"Risperidone versus olanzapine for schizophrenia","author":"Jayaram","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0106|cit106","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(89)90153-4","article-title":"The schedule for the deficit syndrome: An instrument for research in schizophrenia","volume":"30","author":"Kirkpatrick","year":"1989","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD004161.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD004161.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004161.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007474.pub2","article-title":"Risperidone dose for schizophrenia","author":"Li","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"s334","key":"10.1002\/14651858.CD004161.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerd","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD004161.pub2-BIB0115|cit115","first-page":"23","article-title":"Cost of schizophrenia in England","volume":"10","author":"Mangalore","year":"2007","journal-title":"Journal of Mental Health Policy and Economics"},{"issue":"6","key":"10.1002\/14651858.CD004161.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD004161.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"Journal of Sex and Marital Therapy"},{"issue":"1","key":"10.1002\/14651858.CD004161.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"issue":"15","key":"10.1002\/14651858.CD004161.pub2-BIB0120|cit120","first-page":"1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","journal-title":"2001"},{"issue":"11","key":"10.1002\/14651858.CD004161.pub2-BIB0121|cit121","first-page":"1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz","year":"1988","journal-title":"Hospital Community Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD004161.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2012.06.013","article-title":"Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia","volume":"140","author":"Nafees","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0920-9964(03)80260-8","article-title":"Risperdal CONSTA\u2122: Prolonged-release injectable delivery of risperidone using Medisorb\u00ae Microsphere Technology","volume":"60","author":"Ramstack","year":"2003","journal-title":"Schizophrenia"},{"issue":"6","key":"10.1002\/14651858.CD004161.pub2-BIB0125|cit125","first-page":"658","article-title":"New antipsychotics in the treatment of schizophrenia. A European survey","volume":"25","author":"Sarfati","year":"1999","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD004161.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"issue":"6","key":"10.1002\/14651858.CD004161.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double- blind comparison with placebo","volume":"54","author":"Small","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD004161.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1176\/ajp.154.9.1248","article-title":"Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD004161.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD004161.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"issue":"7","key":"10.1002\/14651858.CD004161.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD004161.pub2-BIB0132|cit132","first-page":"105","article-title":"Medication noncompliance in schizophrenia: codification and update","volume":"14","author":"Young","year":"1986","journal-title":"Bulletin of the American Academy of Psychiatry and the Law"},{"issue":"4","key":"10.1002\/14651858.CD004161.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004161","article-title":"Depot risperidone for schizophrenia","author":"Hosalli","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004161.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:51:25Z","timestamp":1748875885000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004161.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,4,14]]},"references-count":133,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004161.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,14]]}}}